<p>瑞士銀行集團在最近向證券交易委員會提交的 13F 表格中披露，第四季度將其在 Eton Pharmaceuticals, Inc.（納斯達克代碼：ETON - 免費報告）的股份減少了 42.5%。該公司在季度內出售了 93,687 股後，持有 126,674 股 Eton 的股票。截至最近一次向證券交易委員會的提交，瑞士銀行集團持有 Eton Pharmaceuticals 0.47% 的股份，價值 2,142,000 美元。</p>
<p>獲取 <strong>Eton Pharmaceuticals</strong> 的提醒：</p>
<p>其他幾家機構投資者和對沖基金最近也增持或減持了在 ETON 的股份。Millennium Management LLC 在第一季度將其在 Eton Pharmaceuticals 的持股增加了 156.3%。Millennium Management LLC 現在擁有 355,929 股該公司的股票，價值 4,620,000 美元，此前在此期間又購買了 217,042 股。高盛集團在第一季度將其在 Eton Pharmaceuticals 的持股增加了 34.9%。高盛集團現在擁有 175,220 股該公司的股票，價值 2,274,000 美元，此前在此期間又購買了 45,341 股。Jane Street Group LLC 在第一季度將其在 Eton Pharmaceuticals 的持股增加了 49.1%。Jane Street Group LLC 現在擁有 95,919 股該公司的股票，價值 1,245,000 美元，此前在此期間又購買了 31,596 股。摩根大通在第二季度將其在 Eton Pharmaceuticals 的持股增加了 114.5%。摩根大通現在擁有 242,580 股該公司的股票，價值 3,457,000 美元，此前在此期間又購買了 129,467 股。最後，Legal &amp; General Group Plc 在第二季度以約 41,000 美元的價格獲得了 Eton Pharmaceuticals 的新頭寸。目前，27.86% 的股票由機構投資者和對沖基金持有。</p>
<h2>內部交易活動</h2>
<p>在 Eton Pharmaceuticals 的其他消息中，內部人士 David Krempa 於 5 月 27 日星期三出售了 19,679 股該公司的股票。股票以平均價格 31.47 美元出售，總價值為 619,298.13 美元。出售後，內部人士持有 25,249 股該公司的股票，價值 794,586.03 美元。這代表了他們持股的 43.80% 的減少。該出售在向證券交易委員會提交的文件中披露，該文件可通過 SEC 網站訪問。內部人士在上個季度共出售了價值 3,229,921 美元的 100,000 股公司股票。16.49% 的股票由公司內部人士持有。</p>
<h2>分析師評級調整</h2>
<p>幾位研究分析師對 ETON 股票發表了看法。Craig Hallum 在 3 月 20 日的研究報告中將 Eton Pharmaceuticals 的目標價格從 30.00 美元上調至 35.00 美元，並給予該股票 &#34;買入&#34; 評級。B. Riley Financial 在 3 月 20 日的研究報告中將 Eton Pharmaceuticals 的目標價格從 26.00 美元上調至 31.00 美元，並給予該股票 &#34;買入&#34; 評級。HC Wainwright 在 5 月 15 日的研究報告中將 Eton Pharmaceuticals 的目標價格從 52.00 美元上調至 57.00 美元，並給予該股票 &#34;買入&#34; 評級。Wall Street Zen 在 3 月 21 日的研究報告中將 Eton Pharmaceuticals 的評級從 &#34;持有&#34; 上調至 &#34;買入&#34;。最後，Zacks Research 在 4 月 17 日的報告中將 Eton Pharmaceuticals 的評級從 &#34;強力買入&#34; 下調至 &#34;持有&#34;。三位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Eton Pharmaceuticals 目前的共識評級為 &#34;持有&#34;，平均目標價格為 41.00 美元。</p>
<p><strong>閲讀我們關於 ETON 的最新報告</strong></p>
<h2>Eton Pharmaceuticals 股票上漲 3.5%</h2>
<p>NASDAQ ETON 的股票在週四開盤時為 32.40 美元。Eton Pharmaceuticals, Inc. 的 12 個月低點為 13.09 美元，12 個月高點為 35.66 美元。該公司的市值為 8.8744 億美元，市盈率為 -462.79，貝塔值為 0.82。該公司的債務與股本比率為 0.62，流動比率為 1.21，速動比率為 0.88。該公司的 50 日移動平均線為 26.59 美元，200 日移動平均線為 20.03 美元。</p>
<p>Eton Pharmaceuticals（納斯達克：ETON - 獲取免費報告）最近在 5 月 14 日星期四公佈了季度財報。該公司報告每股收益（EPS）為 0.05 美元，低於共識預期的 0.10 美元（差額為 0.05 美元）。Eton Pharmaceuticals 的淨利潤率為 -1.70%，股本回報率為 -5.68%。該業務在季度內的收入為 2427 萬美元，而分析師的預期為 2231 萬美元。股票分析師預計 Eton Pharmaceuticals, Inc. 在當前財政年度將發佈 0.82 的每股收益。</p>
<h2>Eton Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Eton Pharmaceuticals, Inc. 是一家專注於開發、生產和商業化針對罕見和被忽視疾病的仿製藥和專有藥物的專業製藥公司。公司總部位於佛羅里達州西棕櫚灘，利用其在激素療法和複雜分子方面的專業知識，解決患者需求高、競爭有限的治療領域。自 2016 年成立以來，Eton 一直致力於建立一個多元化的產品組合，將成熟的仿製藥與針對性品牌產品相結合。</p>
<p>該公司的產品線包括甲狀腺激素替代藥物，如干燥甲狀腺和利奧甲狀腺素，以及用於弓形蟲病的吡美莫司片。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Eton Pharmaceuticals</li>
<li>Abercrombie 在強勁的第一季度財報後反彈，延續勝利之勢</li>
<li>TeraWulf 投資於電力基礎設施以引領人工智能建設</li>
<li>亞馬遜的 Alexa 購物功能加強了已經強勁的牛市論點</li>
<li>Keysight：人工智能和國防股票看到大幅目標價格提升</li>
</ul>
<p><strong>想知道其他對 ETON 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Eton Pharmaceuticals, Inc. (NASDAQ:ETON - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Eton Pharmaceuticals 嗎？</h2>
<p>在考慮 Eton Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Eton Pharmaceuticals 並不在名單上。</p>
<p>雖然 Eton Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ETON

標普生物技術 3 倍做多 - Direxion

納斯達克生物科技指數 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

美國制藥 ETF - iShares

標普生物技術 ETF - SPDR

<p>瑞士銀行集團在第四季度將其在 Eton Pharmaceuticals, Inc.的持股減少了 42.5%，目前持有 126,674 股，價值 214 萬美元。其他機構投資者，包括千禧管理公司和高盛，增加了他們的持股。內部人士 David Krempa 出售了 19,679 股，減少了 43.80% 的持股比例。分析師對 ETON 的評級意見不一，普遍評級為 “持有”，平均目標價為 41.00 美元。Eton 的股票開盤價為 32.40 美元，市值為 8.8744 億美元</p>

<p>UBS Group AG reduced its stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 42.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 126,674 shares of the company's stock after selling 93,687 shares during the quarter. UBS Group AG owned 0.47% of Eton Pharmaceuticals worth $2,142,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>瑞士銀行集團在最近向證券交易委員會提交的 13F 表格中披露，第四季度將其在 Eton Pharmaceuticals, Inc.（納斯達克代碼：ETON - 免費報告）的股份減少了 42.5%。該公司在季度內出售了 93,687 股後，持有 126,674 股 Eton 的股票。截至最近一次向證券交易委員會的提交，瑞士銀行集團持有 Eton Pharmaceuticals 0.47% 的股份，價值 2,142,000 美元。</p>
</div><p>Get <strong>Eton Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Eton Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other institutional investors and hedge funds also recently added to or reduced their stakes in ETON. Millennium Management LLC grew its position in Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company's stock worth $4,620,000 after buying an additional 217,042 shares during the period. Goldman Sachs Group Inc. grew its position in Eton Pharmaceuticals by 34.9% during the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company's stock worth $2,274,000 after buying an additional 45,341 shares during the period. Jane Street Group LLC grew its position in Eton Pharmaceuticals by 49.1% during the first quarter. Jane Street Group LLC now owns 95,919 shares of the company's stock worth $1,245,000 after buying an additional 31,596 shares during the period. JPMorgan Chase &amp; Co. grew its position in Eton Pharmaceuticals by 114.5% during the second quarter. JPMorgan Chase &amp; Co. now owns 242,580 shares of the company's stock worth $3,457,000 after buying an additional 129,467 shares during the period. Finally, Legal &amp; General Group Plc acquired a new position in Eton Pharmaceuticals during the second quarter worth about $41,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金最近也增持或減持了在 ETON 的股份。Millennium Management LLC 在第一季度將其在 Eton Pharmaceuticals 的持股增加了 156.3%。Millennium Management LLC 現在擁有 355,929 股該公司的股票，價值 4,620,000 美元，此前在此期間又購買了 217,042 股。高盛集團在第一季度將其在 Eton Pharmaceuticals 的持股增加了 34.9%。高盛集團現在擁有 175,220 股該公司的股票，價值 2,274,000 美元，此前在此期間又購買了 45,341 股。Jane Street Group LLC 在第一季度將其在 Eton Pharmaceuticals 的持股增加了 49.1%。Jane Street Group LLC 現在擁有 95,919 股該公司的股票，價值 1,245,000 美元，此前在此期間又購買了 31,596 股。摩根大通在第二季度將其在 Eton Pharmaceuticals 的持股增加了 114.5%。摩根大通現在擁有 242,580 股該公司的股票，價值 3,457,000 美元，此前在此期間又購買了 129,467 股。最後，Legal &amp; General Group Plc 在第二季度以約 41,000 美元的價格獲得了 Eton Pharmaceuticals 的新頭寸。目前，27.86% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部交易活動</h2>
</div><p>In other Eton Pharmaceuticals news, insider David Krempa sold 19,679 shares of the company's stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total value of $619,298.13. Following the sale, the insider owned 25,249 shares of the company's stock, valued at $794,586.03. This represents a 43.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 100,000 shares of company stock valued at $3,229,921 over the last quarter. 16.49% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在 Eton Pharmaceuticals 的其他消息中，內部人士 David Krempa 於 5 月 27 日星期三出售了 19,679 股該公司的股票。股票以平均價格 31.47 美元出售，總價值為 619,298.13 美元。出售後，內部人士持有 25,249 股該公司的股票，價值 794,586.03 美元。這代表了他們持股的 43.80% 的減少。該出售在向證券交易委員會提交的文件中披露，該文件可通過 SEC 網站訪問。內部人士在上個季度共出售了價值 3,229,921 美元的 100,000 股公司股票。16.49% 的股票由公司內部人士持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>Several research analysts have weighed in on ETON shares. Craig Hallum upped their target price on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 20th. B. Riley Financial upped their target price on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 20th. HC Wainwright upped their target price on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, May 15th. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, March 21st. Finally, Zacks Research downgraded shares of Eton Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, April 17th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Eton Pharmaceuticals presently has a consensus rating of &#34;Hold&#34; and an average target price of $41.00.</p>
<div class="lb-trans"><p>幾位研究分析師對 ETON 股票發表了看法。Craig Hallum 在 3 月 20 日的研究報告中將 Eton Pharmaceuticals 的目標價格從 30.00 美元上調至 35.00 美元，並給予該股票 &#34;買入&#34; 評級。B. Riley Financial 在 3 月 20 日的研究報告中將 Eton Pharmaceuticals 的目標價格從 26.00 美元上調至 31.00 美元，並給予該股票 &#34;買入&#34; 評級。HC Wainwright 在 5 月 15 日的研究報告中將 Eton Pharmaceuticals 的目標價格從 52.00 美元上調至 57.00 美元，並給予該股票 &#34;買入&#34; 評級。Wall Street Zen 在 3 月 21 日的研究報告中將 Eton Pharmaceuticals 的評級從 &#34;持有&#34; 上調至 &#34;買入&#34;。最後，Zacks Research 在 4 月 17 日的報告中將 Eton Pharmaceuticals 的評級從 &#34;強力買入&#34; 下調至 &#34;持有&#34;。三位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Eton Pharmaceuticals 目前的共識評級為 &#34;持有&#34;，平均目標價格為 41.00 美元。</p>
</div><p><strong>Read Our Latest Report on ETON</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 ETON 的最新報告</strong></p>
</div><h2>Eton Pharmaceuticals Stock Up 3.5%</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals 股票上漲 3.5%</h2>
</div><p>Shares of NASDAQ ETON opened at $32.40 on Thursday. Eton Pharmaceuticals, Inc. has a 12-month low of $13.09 and a 12-month high of $35.66. The company has a market capitalization of $887.44 million, a PE ratio of -462.79 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88. The firm's 50-day moving average is $26.59 and its two-hundred day moving average is $20.03.</p>
<div class="lb-trans"><p>NASDAQ ETON 的股票在週四開盤時為 32.40 美元。Eton Pharmaceuticals, Inc. 的 12 個月低點為 13.09 美元，12 個月高點為 35.66 美元。該公司的市值為 8.8744 億美元，市盈率為 -462.79，貝塔值為 0.82。該公司的債務與股本比率為 0.62，流動比率為 1.21，速動比率為 0.88。該公司的 50 日移動平均線為 26.59 美元，200 日移動平均線為 20.03 美元。</p>
</div><p>Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The business had revenue of $24.27 million during the quarter, compared to analysts' expectations of $22.31 million. Equities analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals（納斯達克：ETON - 獲取免費報告）最近在 5 月 14 日星期四公佈了季度財報。該公司報告每股收益（EPS）為 0.05 美元，低於共識預期的 0.10 美元（差額為 0.05 美元）。Eton Pharmaceuticals 的淨利潤率為 -1.70%，股本回報率為 -5.68%。該業務在季度內的收入為 2427 萬美元，而分析師的預期為 2231 萬美元。股票分析師預計 Eton Pharmaceuticals, Inc. 在當前財政年度將發佈 0.82 的每股收益。</p>
</div><h2>Eton Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals, Inc. 是一家專注於開發、生產和商業化針對罕見和被忽視疾病的仿製藥和專有藥物的專業製藥公司。公司總部位於佛羅里達州西棕櫚灘，利用其在激素療法和複雜分子方面的專業知識，解決患者需求高、競爭有限的治療領域。自 2016 年成立以來，Eton 一直致力於建立一個多元化的產品組合，將成熟的仿製藥與針對性品牌產品相結合。</p>
</div><p>The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.</p>
<div class="lb-trans"><p>該公司的產品線包括甲狀腺激素替代藥物，如干燥甲狀腺和利奧甲狀腺素，以及用於弓形蟲病的吡美莫司片。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Eton Pharmaceuticals</li>
<li>Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak</li>
<li>TeraWulf Bets on Power Infrastructure to Lead AI Build-Out</li>
<li>Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case</li>
<li>Keysight: The AI and Defense Stock Seeing Big Price Target Boosts</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Eton Pharmaceuticals</li>
<li>Abercrombie 在強勁的第一季度財報後反彈，延續勝利之勢</li>
<li>TeraWulf 投資於電力基礎設施以引領人工智能建設</li>
<li>亞馬遜的 Alexa 購物功能加強了已經強勁的牛市論點</li>
<li>Keysight：人工智能和國防股票看到大幅目標價格提升</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ETON?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對 ETON 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Eton Pharmaceuticals, Inc. (NASDAQ:ETON - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ETON"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eton Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Eton Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Eton Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Eton Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Eton Pharmaceuticals 並不在名單上。</p>
</div><p>While Eton Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Eton Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Eton Pharmaceuticals, Inc. $ETON Shares Sold by UBS Group AG

Market Beat

Eton Pharmaceuticals

瑞銀集團

高盛

摩根大通

Legal & General Group Plc

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存託優先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

瑞銀集團出售了 Eton Pharmaceuticals, Inc. $ETON 的股票